公开(公告)号：US20150232556A1

公开(公告)日：2015-08-20

申请号：US14662349

申请日：2015-03-19

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  SIMON KOLLNBERGER ,  BENJAMIN ROSSI ,  HÉLÈNE SICARD ,  CARINE PATUREL ,  STÉPHANIE CORNEN ,  STÉPHANIE ZERBIB

IPC: C07K16/28 ,  G01N33/569

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

Abstract translation: 本发明涉及使用特异性结合KIR3DL2的抗体（例如单克隆抗体），抗体片段及其衍生物来治疗癌症和炎性疾病的方法。 本发明还涉及抗体，产生这种抗体的细胞; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 含有该组合物的药物组合物。

公开(公告)号：US20210238285A1

公开(公告)日：2021-08-05

申请号：US17225160

申请日：2021-04-08

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US20210122821A1

公开(公告)日：2021-04-29

申请号：US17128241

申请日：2020-12-21

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CAROLINE DENIS ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizaing agents and PD-1 neutralizing agents for the treatment of cancer.

公开(公告)号：US20200332008A1

公开(公告)日：2020-10-22

申请号：US16924288

申请日：2020-07-09

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

公开(公告)号：US20200299383A1

公开(公告)日：2020-09-24

申请号：US16894937

申请日：2020-06-08

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US20190071514A1

公开(公告)日：2019-03-07

申请号：US16084249

申请日：2017-03-14

Applicant: INNATE PHARMA ,  OREGA BIOTECH

Inventor： LAURENT GAUTHIER ,  CARINE PATUREL ,  IVAN PERROT

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.

公开(公告)号：US20140234323A1

公开(公告)日：2014-08-21

申请号：US14268242

申请日：2014-05-02

Applicant: Innate Pharma

Inventor： KARINE CHEMIN ,  LAURENT GAUTHIER ,  YANNIS MOREL ,  CARINE PATUREL ,  AGNES TISSERANT

IPC: C07K16/30 ,  G01N33/574

CPC classification number: C07K16/30 ,  C07K16/2896 ,  G01N33/57415 ,  G01N33/57492

Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.

Abstract translation: 本发明涉及特异性结合存在于细胞表面上的TLR3细胞受体的抗体，抗体片段及其衍生物。 本发明还涉及产生这种抗体的杂交瘤; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 包含它们的药物组合物; 使用抗体检测细胞表面上的TLR3水平的方法，以及在受试者中用于诊断或治疗目的的此类抗体和组合物的用途。